Company intelligence / Profile preview

BioSig Technologies

Los Angeles, California, United Statesbiosig.com ↗

Ownership: Public · BSGM
Employees: ~5
Development stage: Commercial

Overview

BioSig’s PURE EP™ Platform is FDA 510(k) cleared and has been used in over 3,000 patient procedures by more than 80 physicians at over 21 hospitals. Clinical use demonstrates improved intracardiac signal fidelity and procedural efficiency for cardiac ablation[6][8][10].

Therapeutic areas: Cardiovascular
Modalities: Medical device (signal processing platform)Digital health technology (intracardiac signal visualization)
Industry: Physiological Monitoring

Partnerships

Mayo Foundation for research on AI/machine learning-powered software for the PURE EP system[7]Summit Blue Capital for leasing/finance of the PURE EP system[6]

Financials

Market cap: $191.1M
Total revenue: $0
Enterprise value: $180.1M

Beyond the preview

Go deeper on BioSig Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioSig Technologies.

Explore the full profile